PURPOSE: To compare the risk of primary open-angle glaucoma (POAG) and ocular hypertension, in patients taking glucagon like peptide-1 receptor agonists (GLP-1RAs) versus alternative weight loss medications in patients with obesity. DESIGN: A retrospective cohort study of the TriNetX research network was conducted by analyzing international electronic health record (EHR) data from January 2004 to December 2024. PARTICIPANTS: Non-diabetic patients with a diagnosis of being overweight or having obesity who were treated with either GLP-1RAs or alternative weight loss medications including orlistat, phentermine-topiramate, bupropion-naltrexone, or setmelanotide. METHODS: Patients were assessed for outcomes at 3 and 5 years. Propensity score matching (PSM) was conducted between cohorts matched for baseline demographics, comorbidities, and medication use. Risk ratios (RR) and 95% confidence intervals (CI) were subsequently calculated. MAIN OUTCOME MEASURES: Risk of POAG and ocular hypertension. RESULTS: After PSM, both cohorts contained 61,057 patients. The risk of both POAG and ocular hypertension were reduced significantly in the GLP-1RA group at both 3 and 5 years of follow up. There was a 50.4% reduced risk at 3 years (RR: 0.496, 95% CI: 0.371 - 0.664) and a 58.5% reduced risk at 5 years (RR 0.415, 95% CI: 0.316 - 0.545) for developing POAG. There was a reduced risk of 55.9% at 3 years (RR: 0.441, 95% CI 0.318 - 0.611) and 65.8% at 5 years (RR: 0.342, 95% CI: 0.250 - 0.466) for developing ocular hypertension. CONCLUSIONS: In non-diabetic patients, the use of GLP-1RAs exhibited a significantly reduced risk of POAG and ocular hypertension compared to alternative weight loss therapy at 3- and 5-year intervals. These results underscore the utility of GLP-1RAs in glaucoma prevention and management and highlights yet another potential indication for this class of medications beyond glycemic control.